课题基金 / 基金详情

Role of the BCL 6 Proto Oncogene in B Cell Lymphomas

Role of the BCL 6 Proto Oncogene in B Cell Lymphomas
BCL 6 原癌基因在 B 细胞淋巴瘤中的作用
批准号:
7767766
负责人:
Bihui Hilda Ye
金额:
$36.5万
依托单位国家:
美国
项目类别:
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-05-01 至 2012-02-28

项目摘要

项目成果

Bihui Hilda Ye的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The main objective of this project is to understand how the BCL-6 gene is regulated and how its functional interaction with the IL-6/STAT3 pathway may contribute to its role in normal B cells and B cell lymphomas. BCL-6 encodes a POZ-zinc finger type transcription represser that has been thought to repress transcription in vivo by recruiting corepressors SMRT/NCoR/BCoR and NuRD/MTA3. BCL-6 is constitutively expressed at high levels in many diffuse large cell lymphomas (DLBCL) due to genetic alterations that override a negative autoregulatory mechanism governing BCL-6 transcription. In the normal lymphoid system, high level BCL-6 protein is specifically found in B cells within the germinal centers (GC) and BCL-6 function is critical for GC formation. Our recent work indicates that BCL-6 autoregulation works in a SMRT/NCoR/BCoR-and NuRD/MTA3 independent manner. Therefore in Aim 1, we plan to characterize specific chromatin changes involved in BCL-6 autoregulation and identify the novel corepressor used by the BCL-6 protein to regulate its own transcription. Our recent study also uncovered a set of very novel findings indicating that BCL6 is a powerful inhibitor of STATS expression/activation, and that STATS is constitutively activated in the activated B cell like DLBCL (ABC-DLBCL) and required for cell proliferation and survival. Thus, experiments in Aim 2 are designed to characterize the functional relationship between BCL6 and STATS in plasma cell differentiation, determine the cause of constitutive STATS activation in ABC-DLBCL, and study the tumorigenic potential of a constitutively activated STATS in vivo. Since ABC-DLBCL is often associated with poor treatment outcome, we also plan to pursue collaborative studies to evaluate the prognostic value of STATS activation in primary DLBCL either as a single marker or in combination with BCL6. Our studies should provide valuable information regarding a novel aspect of BCL6's transrepression mechanism and more importantly, further our understanding of the roles played by BCL6 and STATS in the genetics and biology of B cell lymphomas.
期刊论文(10)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1002/path.2031
发表时间: 2006
期刊: The Journal of pathology
影响因子: --
作者: [Wang,X, Ding,BB, Mendez,LM, Papetti,M, Ye,BH]
通讯作者: Ye,BH
DOI: 10.1093/jmcb/mjp032
发表时间: 2010-02
期刊: Journal of molecular cell biology
影响因子: 5.5
作者: [Enguang Bi;B. Ye]
通讯作者: Enguang Bi;B. Ye
DOI: 10.4049/jimmunol.1201678
发表时间: 2013-02-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Ding BB, Bi E, Chen H, Yu JJ, Ye BH]
通讯作者: Ye BH
Epigenetic Alterations and Targeted Therapies in North American ATLL
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS
ROLE OF THE BCL 6 PROTO ONCOGENE IN B CELL LYMPHOMAS
海外基金